Biotech Showcase™ 2018: Exelixis CEO Michael Morrissey shares high hopes for cabozantinib скачать в хорошем качестве

Biotech Showcase™ 2018: Exelixis CEO Michael Morrissey shares high hopes for cabozantinib

https://ebdgroup.knect365.com/biotech... Exelixis CEO Michael Morrissey speaks to Scrip senior writer Emily Hayes about the launch of the drug Cabometyx (cabozantinib) in previously untreated renal cell carcinoma, following FDA approval for this use in mid-December. The company was launch-ready at the time of the announcement and prepared to ship product within hours of approval, Morrissey explains in an interview on January 9 at the 2018 Biotech Showcase meeting in San Francisco. It's still early to gauge how the launch is going, but the company reports that it had good traction in December and is excited to be out talking to customers and doctors about the new label. Morrissey also comments on use of the drug in liver cancer, as data from the Phase III CELESTIAL study in this tumor type are being presented at the ASCO GI meeting on January 18 in San Francisco, as well as other indications.